The enhanced antitumor immunity and response to immune checkpoint inhibitors seen in Irg1-deficient mice, which otherwise exhibit normal development, underscore IRG1 as a compelling target for cancer immunotherapy (Chen et al., 2023; Gu et al., 2023; Zhao et al., 2022). The gene discussed is ACOD1; the disease is cancer.